EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Hope S. Rugo, Johannes Ettl, Natasha E. Woodward, Sara A. Hurvitz, Anthony Goncalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A. Mina, Miguel Martin, Henri Hubert Roche, Young-Hyuck Im, Denka Markova, Iulia Cristina Tudor, Wolfgang Eiermann, Joanne Lorraine Blum, Alison L. Hannah, Jennifer Keating Litton
Institutions: UCSF Helen Diller Family Comprehensive Cancer Center, TUM Klinikum, Technical University of Munich, Mater Health Services, University of California, Los Angeles, Institut Paoli-Calmettes, Seoul National University Hospital, Kaiser Permanente Vallejo Medical Center, Kaiser Permanente Northern California, Rabin Medical Center, Banner Health, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón, Institut Claudius Regaud, Samsung Medical Center, Pfizer (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2807659903